Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCCT-lynx1 siRNA
- Development stage
- Preclinical
- Lead developer
- Ophidion
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
OCCT-lynx1 siRNA is a preclinical-stage therapeutic candidate developed by Ophidion for the treatment of cognitive impairment associated with neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The drug utilizes Ophidion's proprietary CNS Carrier Technology (OCCT) platform, which employs a nanoparticle-based "Trojan horse" strategy to deliver small interfering RNA (siRNA) across the blood-brain barrier via intravenous injection. The active ingredient is an siRNA designed to knock down the expression of Lynx1, a membrane-tethered protein that binds to and modulates nicotinic acetylcholine receptors (nAChRs). Lynx1 normally acts as a molecular brake on synaptic plasticity, suppressing memory and learning. By silencing Lynx1 expression, the therapy aims to enhance cholinergic signaling and restore cognitive function. Preclinical studies in mouse models have demonstrated successful target knockdown and improved novel object recognition memory following administration.
- Other names
- OCCT-lynx1 siRNAOCCT-lynx-1 siRNAOCCT-lynx 1 siRNAlynx1 siRNAlynx-1 siRNAlynx 1 siRNA
02
Targets
LYNX1 (Ly6/neurotoxin-like protein 1)
Beyond the preview
Go deeper on OCCT-lynx1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCCT-lynx1 siRNA.